64302-87-0

Usage

Uses

Used in Cancer Treatment:
R162 is used as a glutamate dehydrogenase 1 inhibitor for the treatment of cancer. It targets the GDH1 enzyme, which is commonly upregulated in human cancers, and helps in reducing cell proliferation and metastatic potential.
Used in Anticancer Research:
R162 is used as a useful bioactive chemical compound in anticancer research. It serves as a valuable tool for proof of principal studies, helping researchers understand the role of GDH1 in cancer progression and the potential of R162 as a therapeutic agent.
Used in Drug Development:
R162 is used in the development of new drugs targeting the GDH1 enzyme. Its selective inhibition of GDH1 makes it a promising candidate for the development of novel cancer therapies, particularly for cancers with high GDH1 expression levels.
Used in Cancer Cell Studies:
R162 is used in studies involving cancer cell lines such as H1299 and MDA-MB231. It helps researchers investigate the effects of R162 treatment on cell proliferation, ROS levels, and glutathione peroxidase activity, providing valuable insights into the mechanisms of action of R162 in cancer cells.
Used in Antimetasasis Research:
R162 is used in antimetastasis research, as it has been shown to significantly attenuate metastatic potential in a xenograft mouse model. This makes R162 a valuable tool for studying the role of GDH1 in cancer metastasis and the development of potential antimetastasis therapies.

References

1) Jin?et al. (2015),?Glutamate Dehydrogenase 1 Signals through Antioxidant Glutathione Peroxidase 1 to Regulate Redox Homeostasis and Tumor Growth; Cancer Cell,?27?257 2) Jin?et al.?(2018)?The PLAG1-GDH1 Axis Promotes Anokis Resistance and Tumor Metastasis through CamKK2-AMPK Signaling in LKB1-Deficient Lung Cancer; Mol. Cell,?69?1

Upstream product

• 64302-83-6 1-(prop-2'-enyloxy)anthraquinone 
• 80034-87-3 1-(2'-chloroprop-2'-enyloxy)anthraquinone 
• 129-43-1 1-hydroxyanthraquinone 

Downstream Products

• 1086461-16-6 2-(1-(benzyloxy)-9,10-anthraquinonyl)-acetic acid 
• 1086461-14-4 C₂₃H₁₆O₄ 
• 1086461-12-2 2-allyl-1-benzyloxy-9,10-anthraquinone 

Relevant academic research and scientific papers

REDUCTIVE CLAISEN REARRANGEMENTS OF ANTHRAQUINONE ALLYL ETHERS

Gentle heating of allyloxyanthraquinones with sodium dithionite in dimethylformamide - water effects a rapid and controlled rearrangement to give high yields of 2-allylanthraquinones.

Efficient reductive Claisen rearrangement of prop-2’-enyloxyanthraquinones and 2’-chloroprop-2’-enyloxyanthraquinones with iron powder in ionic liquids

A rapid and selective iron-mediated reductive Claisen rearrangement of various prop-2’-enyloxyanthraquinones and 2’-chloroprop-2’-enyloxyanthraquinones to 1-hydroxy-2-(prop-2’-enyl)anthraquinones and anthrafurandiones is presented. All reactions are carried out in a mixture of ionic liquids, [Bzmim]Cl (1-benzyl-3-methylimidazolium chloride) and [Hmim]BF4 (1-methylimidazolium tetrafluoroborate), in short reaction times (5–35 min). Our study showed that 1-(prop-2’-enyloxy)anthraquinone is more active than 1-(2’-chloroprop-2’-enyloxy)anthraquinone to perform this rearrangement.

Caged trans-4-hydroxy-2-nonenal

(Chemical Equation Presented) A caged 4-hydroxy-2-nonenal (4-HNE) has been prepared and its photochemistry investigated. Upon photolysis, 1 releases 4-HNE in up to 100% yield. From these photolyses, 4-HNE could be isolated in up to 91% yield. 4-HNE is produced under either aerobic or anaerobic conditions. The caging strategy does not require prior preparation of 4-HNE and, therefore, represents a three-step synthetic route to the bioactive enal in 48% overall yield.

Experiments Directed Towards the Synthesis of Anthracyclinones. VIII. Functionalization of Hydroxyanthraquinones by Reductive Claisen Rearrangements

Gentle heating of allyloxyanthraquinones with sodium dithionite in dimethylformamide/water effects a rapid and controlled rearrangement to give high yields of 2-allylhydroxyanthraquinones.Starting from quinizarin, key intermediates for two synthetic routes to 4-demethoxydaunomycinone have been prepared from products by means of two such reductive Claisen rearrangements.